DOCSLIB.ORG

Drug Metabolite

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Drug Metabolite Drug Metabolite Drug metabolite results when a drug is metabolized into a modified form which continues to produce effects. Drug metabolism redox reactions such as heteroatom dealkylations, hydroxylations, heteroatom oxygenations, reductions, and dehydrogenations can yield active metabolites, and in rare cases even conjugation reactions can yield an active metabolite. www.MedChemExpress.com 1 Drug Metabolite Inhibitors & Chemicals (E)-10-Hydroxynortriptyline (E)-10-Hydroxynortriptyline maleate (E-10-OH-NT) Cat. No.: HY-U00050 Cat. No.: HY-100646 (E)-10-Hydroxynortriptyline (E-10-OH-NT) is a (E)-10-Hydroxynortriptyline maleate is a metabolite of Nortriptyline (HY-B1417). metabolite of Nortriptyline. Nortriptyline is a Nortriptyline is a tricyclic antidepressant and tricyclic antidepressant and the main active the main active metabolite of Amitriptyline metabolite of Amitriptyline, and is used to (HY-B0527A). relieve the symptoms of depression. Purity: 99.66% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 5 mg Size: 1 mg, 5 mg (R)-3-Hydroxy Midostaurin (Rac)-3′-Hydroxy simvastatin ((R)-CGP52421) Cat. No.: HY-108263B Cat. No.: HY-136345 (R)-3-Hydroxy Midostaurin ((R)-CGP52421) is a (Rac)-3′-Hydroxy simvastatin is a metabolite of potent kinases inhibitor. (R)-3-Hydroxy Simvastatin. Simvastatin is a competitive Midostaurin is a major metabolite of midostaurin inhibitor of HMG-CoA reductase with a Ki of 0.2 nM. (PKC412; HY-10230) undergoing by the hepatic CYP3A4 enzyme. (R)-3-Hydroxy Midostaurin has the potential for acute myeloid leukemia (AML). Purity: >98% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 1 mg, 5 mg (Rac)-Mono(3,5,5-trimethylhexyl) phthalate (S)-3-Hydroxy Midostaurin Cat. No.: HY-133672 ((S)-CGP52421) Cat. No.: HY-108263A (Rac)-Mono(3,5,5-trimethylhexyl) phthalate is a (S)-3-Hydroxy Midostaurin ((S)-CGP52421) is a important metabolite of commonly used phthalate potent kinases inhibitor with IC50 values of plasticizers. (Rac)-Mono(3,5,5-trimethylhexyl) <400 nM for 13 kinases (VEGFR-2, TRK-A, FLT3, phthalate has immuno-suppressive effect. et). Purity: >98% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 1 mg, 5 mg (S)-O-Desmethyl Venlafaxine N-Oxide (Z)-10-Hydroxynortriptyline Cat. No.: HY-131254 Cat. No.: HY-100646A (S)-O-Desmethyl Venlafaxine N-Oxide is a N-oxyde (Z)-10-Hydroxynortriptyline is a metabolite of of (S)-O-Desmethyl Venlafaxine. O-Desmethyl Nortriptyline. Nortriptyline is a tricyclic Venlafaxine is an active metabolite of antidepressant and the main active metabolite of Venlafaxine. Venlafaxine (HY-B0196) is an Amitriptyline, and is used to relieve the symptoms antidepressant of the serotonin-norepinephrine of depression. reuptake inhibitor (SNRI) class. Purity: >98% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg Size: 1 mg (±)-Equol 1'-Hydroxymidazolam Cat. No.: HY-100583A Cat. No.: HY-118645 (±)-Equol is the racemate of equol. Equol is a 1'-Hydroxymidazolam is a primary active metabolite metabolite of the soy isoflavones, daidzin and of Midazolam, and it is a neuronal depressant daidzein. agent. 1'-Hydroxymidazolam could inhibit neuronal activity add to the effects of Midazolam. Purity: 98.04% Purity: ≥98.0% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg Size: 1 mg, 5 mg 2 Tel: 609-228-6898 Fax: 609-228-5909 Email: [email protected] 13-​cis Acitretin D3 15-Acetyl-deoxynivalenol (Isoacitretin D3; Ro 13-7652 D3) Cat. No.: HY-129240S Cat. No.: HY-N6683 13-cis Acitretin D3 Isoacitretin D3 is a 15-Acetyl-deoxynivalenol is a highly toxic deuterium labeled 13-cis Acitretin. 13-cis trichothecene found in cereals, and a metabolite Acitretin is the metabolite of Acitretin after of deoxynivalenol, exhibits toxicity to HepG2 chronic administration. Acitretin(Ro 10-1670) is a cells. second-generation, systemic retinoid that has been used in the treatment of psoriasis. Purity: >98% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 1 mg, 5 mg 16α-Hydroxyprednisolone 2-Aminoflubendazole (OH-PRED) Cat. No.: HY-117580 Cat. No.: HY-133694 16α-Hydroxyprednisolone is a stereoselective 2-Aminoflubendazole is the metabolite of metabolite of the 22(R) epimer of the Benzimidazoles. Benzimidazoles (BZ) are a class of glucocorticoid budesonide via cytochrome P450 3A drugs with activities against fungi, protozoa, and (CYP3A) enzymes. helminthes. Purity: 98.08% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10 mM × 1 mL, 100 mg Size: 1 mg, 5 mg 2-Hydroxy atorvastatin calcium salt 2-Hydroxy atorvastatin lactone Cat. No.: HY-128828 Cat. No.: HY-136346 2-Hydroxy atorvastatin calcium salt is a hydroxy 2-Hydroxy atorvastatin lactone is a metabolite of metabolite of Atorvastatin calcium salt. Atorvastatin. Atorvastatin is an orally active Atorvastatin is a potent HMG-CoA reductase HMG-CoA reductase inhibitor, has the ability to inhibitor with an IC50 value of 8 nM. effectively decrease blood lipids. Purity: 97.68% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg Size: 1 mg, 5 mg 24, 25-Dihydroxy VD2 3'-Hydroxy Repaglinide (24,25-Dihydroxy vitamin D2) Cat. No.: HY-76801 Cat. No.: HY-135335 24, 25-Dihydroxy VD2 is a hydroxylated metabolite 3'-Hydroxy Repaglinide is a main CYP2C8 metabolite of Vitamin D2; a synthetic analog of Vitamin D. of Repaglinide. Repaglinide is a carbamoylmethyl benzoic acid (CMBA) derivative, which recently has become available for the treatment of type II diabetes. Purity: 99.89% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 10 mg Size: 5 mg 3'-Hydroxy Repaglinide D5 3,4-Dehydro Cilostazol Cat. No.: HY-135335S (OPC-13015) Cat. No.: HY-135910 3'-Hydroxy Repaglinide D5 is the deuterium labeled 3,4-Dehydro Cilostazol (OPC-13015) is an active 3'-Hydroxy Repaglinide. 3'-Hydroxy Repaglinide is metabolite of Cilostazol (CLZ; HY-17464). a main CYP2C8 metabolite of Repaglinide. 3,4-Dehydro Cilostazol is used for pharmacokinetic study. Purity: ≥98.0% Purity: 98.01% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg www.MedChemExpress.com 3 3-Desacetyl Cefotaxime lactone 3-Methoxytyramine hydrochloride Cat. No.: HY-135394 (3-O-methyl Dopamine hydrochloride) Cat. No.: HY-103638 3-Desacetyl Cefotaxime lactone is the active 3-Methoxytyramine hydrochloride is an inactive metabolite of Cefotaxime. Cefotaxime sodium salt metabolite of dopamine which can activate trace is a third-generation cephalosporin antibiotic. amine associated receptor 1 (TAAR1). Purity: >98% Purity: ≥97.0% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 10 mM × 1 mL, 100 mg, 250 mg, 500 mg, 1 g 3α-Hydroxy pravastatin sodium 4'-Hydroxy diclofenac Cat. No.: HY-136347 Cat. No.: HY-15550 3α-Hydroxy pravastatin sodium is the major 4'-Hydroxy diclofenac is an orally active metabolite of Pravastatin. Pravastatin is a metabolite of Diclofenac (HY-15036) by cytochrome competitive HMG-CoA reductase inhibitor. P450 2C9 (CYP2C9). 4'-Hydroxy diclofenac has anti-inflammatory and analgesic properties. Purity: >98% Purity: ≥97.0% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 5 mg 4-Desmethoxy Omeprazole 4-Desmethyl Istradefylline Cat. No.: HY-135111 Cat. No.: HY-135387 4-Desmethoxy Omeprazole is the active metabolite 4-Desmethyl Istradefylline is a metabolite of of Omeprazole. Omeprazole, a proton pump inhibitor Istradefylline. 4-Istradefylline is a very potent, (PPI), is available for treatment of acid-related selective and orally active adenosine A2A receptor gastrointestinal disorders. Omeprazole shows antagonist with Ki of 2.2 nM in experimental competitive inhibition of CYP2C19 activity with a models of Parkinson's disease. Ki of 2 to 6 μM. Purity: >98% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 1 mg, 5 mg 4-Hydroperoxy cyclophosphamide 4-Methylamino antipyrine Cat. No.: HY-117433 Cat. No.: HY-135731 4-Hydroperoxy cyclophosphamide is the active 4-Methylamino antipyrine is an active metabolite metabolite form of the prodrug Cyclophosphamide. of Metamizole. Metamizole is a pyrazolone non-steroidal anti-inflammatory drug (NSAID) and inhibits COX. Metamizole is an nonopioid analgesic drug and can be used for pain and fever. Purity: ≥95.0% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 5 mg, 10 mg Size: 1 mg, 5 mg 4-Methylamino antipyrine hydrochloride 5β-Dihydrocortisol Cat. No.: HY-135731A Cat. No.: HY-N3995 4-Methylamino antipyrine hydrochloride is an 5β-Dihydrocortisol, a metabolite of Cortisol, is a active metabolite of Metamizole. Metamizole is a potential mineralocorticoid. 5β-Dihydrocortisol pyrazolone non-steroidal anti-inflammatory drug can potentiate glucocorticoid activity in raising (NSAID) and inhibits COX. Metamizole is an the intraocular pressure. 5β-Dihydrocortisol nonopioid analgesic drug and can be used for pain causes breast cancer cell apoptosis. and fever. Purity: >98% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 25 mg, 50 mg, 100 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg 4 Tel: 609-228-6898 Fax: 609-228-5909 Email: [email protected] 5β-​Dutasteride 6-Azathymine acid Cat. No.: HY-135386 Cat. No.: HY-136560 5β-Dutasteride is the S configuration of 6-Azathymine acid is a metabolite of Pymetrozine. Dutasteride. 5β-Dutasteride is a potent inhibitor Pymetrozine is active against plant-sucking of both 5 alpha-reductase isozymes. insects, such as aphids and whiteflies in vegetables, cotton, field crops and fruits and affects the nervous regulation of feeding behavior.
Load more

Recommended publications
  • Product List March 2019 - Page 1 of 53
    Wessex has been sourcing and supplying active substances to medicine manufacturers since its incorporation in 1994. We supply from known, trusted partners working to full cGMP and with full regulatory support. Please contact us for details of the following products. Product CAS No. ( R)-2-Methyl-CBS-oxazaborolidine 112022-83-0 (-) (1R) Menthyl Chloroformate 14602-86-9 (+)-Sotalol Hydrochloride 959-24-0 (2R)-2-[(4-Ethyl-2, 3-dioxopiperazinyl) carbonylamino]-2-phenylacetic 63422-71-9 acid (2R)-2-[(4-Ethyl-2-3-dioxopiperazinyl) carbonylamino]-2-(4- 62893-24-7 hydroxyphenyl) acetic acid (r)-(+)-α-Lipoic Acid 1200-22-2 (S)-1-(2-Chloroacetyl) pyrrolidine-2-carbonitrile 207557-35-5 1,1'-Carbonyl diimidazole 530-62-1 1,3-Cyclohexanedione 504-02-9 1-[2-amino-1-(4-methoxyphenyl) ethyl] cyclohexanol acetate 839705-03-2 1-[2-Amino-1-(4-methoxyphenyl) ethyl] cyclohexanol Hydrochloride 130198-05-9 1-[Cyano-(4-methoxyphenyl) methyl] cyclohexanol 93413-76-4 1-Chloroethyl-4-nitrophenyl carbonate 101623-69-2 2-(2-Aminothiazol-4-yl) acetic acid Hydrochloride 66659-20-9 2-(4-Nitrophenyl)ethanamine Hydrochloride 29968-78-3 2,4 Dichlorobenzyl Alcohol (2,4 DCBA) 1777-82-8 2,6-Dichlorophenol 87-65-0 2.6 Diamino Pyridine 136-40-3 2-Aminoheptane Sulfate 6411-75-2 2-Ethylhexanoyl Chloride 760-67-8 2-Ethylhexyl Chloroformate 24468-13-1 2-Isopropyl-4-(N-methylaminomethyl) thiazole Hydrochloride 908591-25-3 4,4,4-Trifluoro-1-(4-methylphenyl)-1,3-butane dione 720-94-5 4,5,6,7-Tetrahydrothieno[3,2,c] pyridine Hydrochloride 28783-41-7 4-Chloro-N-methyl-piperidine 5570-77-4
    [Show full text]
  • Drug–Drug Salt Forms of Ciprofloxacin with Diflunisal and Indoprofen
    CrystEngComm View Article Online COMMUNICATION View Journal | View Issue Drug–drug salt forms of ciprofloxacin with diflunisal and indoprofen† Cite this: CrystEngComm,2014,16, 7393 Partha Pratim Bag, Soumyajit Ghosh, Hamza Khan, Ramesh Devarapalli * Received 27th March 2014, and C. Malla Reddy Accepted 12th June 2014 DOI: 10.1039/c4ce00631c www.rsc.org/crystengcomm Two salt forms of a fluoroquinolone antibacterial drug, Crystal engineering approach has been effectively ciprofloxacin (CIP), with non-steroidal anti-inflammatory drugs, utilized in recent times in the synthesis of new forms particu- diflunisal (CIP/DIF) and indoprofen (CIP/INDP/H2O), were synthe- larly by exploiting supramolecular synthons. Hence the sized and characterized by PXRD, FTIR, DSC, TGA and HSM. Crystal identification of synthons that can be transferred across Creative Commons Attribution-NonCommercial 3.0 Unported Licence. structure determination allowed us to study the drug–drug different systems is important. For example, synthon trans- interactions and the piperazine-based synthon (protonated ferability in cytosine and lamivudine salts was recently dem- piperazinecarboxylate) in the two forms, which is potentially useful onstrated by Desiraju and co-workers by IR spectroscopy for the crystal engineering of new salt forms of many piperazine- studies.20a Aakeröy and co-workers successfully estab- based drugs. lished the role of synthon transferability (intermolecular amide⋯amide synthons) in the assembly and organization of Multicomponent pharmaceutical forms consisting of an bidentate acetylacetonate (acac) and acetate “paddlewheel” active pharmaceutical ingredient (API) and an inactive 20b complexes of a variety of metal(II)ions. Recently Das et al. co-former,whichisideallyagenerally recognized as safe – have reported the gelation behaviour in various diprimary This article is licensed under a 1 3 (GRAS) substance, have been well explored in recent times.
    [Show full text]
  • PMBJP Product.Pdf
    Sr. Drug Generic Name of the Medicine Unit Size MRP Therapeutic Category No. Code Analgesic & Antipyretic / Muscle 1 1 Aceclofenac 100mg and Paracetamol 325 mg Tablet 10's 10's 8.00 relaxants Analgesic & Antipyretic / Muscle 2 2 Aceclofenac Tablets IP 100mg 10's 10's 4.37 relaxants Acetaminophen 325 + Tramadol Hydrochloride 37.5 film Analgesic & Antipyretic / Muscle 3 4 10's 8.00 coated Tablet 10's relaxants Analgesic & Antipyretic / Muscle 4 5 ASPIRIN Tablets IP 150 mg 14's 14's 2.70 relaxants DICLOFENAC 50 mg+ PARACETAMOL 325 mg+ Analgesic & Antipyretic / Muscle 5 6 10's 11.30 CHLORZOXAZONE 500 mg Tablets 10's relaxants Diclofenac Sodium 50mg + Serratiopeptidase 10mg Tablet Analgesic & Antipyretic / Muscle 6 8 10's 12.00 10's relaxants Analgesic & Antipyretic / Muscle 7 9 Diclofenac Sodium (SR) 100 mg Tablet 10's 10's 6.12 relaxants Analgesic & Antipyretic / Muscle 8 10 Diclofenac Sodium 25mg per ml Inj. IP 3 ml 3 ml 2.00 relaxants Analgesic & Antipyretic / Muscle 9 11 Diclofenac Sodium 50 mg Tablet 10's 10's 2.90 relaxants Analgesic & Antipyretic / Muscle 10 12 Etoricoxilb Tablets IP 120mg 10's 10's 33.00 relaxants Analgesic & Antipyretic / Muscle 11 13 Etoricoxilb Tablets IP 90mg 10's 10's 25.00 relaxants Analgesic & Antipyretic / Muscle 12 14 Ibuprofen 400 mg + Paracetamol 325 mg Tablet 10's 15's 5.50 relaxants Analgesic & Antipyretic / Muscle 13 15 Ibuprofen 200 mg film coated Tablet 10's 10's 1.80 relaxants Analgesic & Antipyretic / Muscle 14 16 Ibuprofen 400 mg film coated Tablet 10's 15's 3.50 relaxants Analgesic & Antipyretic
    [Show full text]
  • Management of Side Effects of Antipsychotics
    Management of side effects of antipsychotics Oliver Freudenreich, MD, FACLP Co-Director, MGH Schizophrenia Program www.mghcme.org Disclosures I have the following relevant financial relationship with a commercial interest to disclose (recipient SELF; content SCHIZOPHRENIA): • Alkermes – Consultant honoraria (Advisory Board) • Avanir – Research grant (to institution) • Janssen – Research grant (to institution), consultant honoraria (Advisory Board) • Neurocrine – Consultant honoraria (Advisory Board) • Novartis – Consultant honoraria • Otsuka – Research grant (to institution) • Roche – Consultant honoraria • Saladax – Research grant (to institution) • Elsevier – Honoraria (medical editing) • Global Medical Education – Honoraria (CME speaker and content developer) • Medscape – Honoraria (CME speaker) • Wolters-Kluwer – Royalties (content developer) • UpToDate – Royalties, honoraria (content developer and editor) • American Psychiatric Association – Consultant honoraria (SMI Adviser) www.mghcme.org Outline • Antipsychotic side effect summary • Critical side effect management – NMS – Cardiac side effects – Gastrointestinal side effects – Clozapine black box warnings • Routine side effect management – Metabolic side effects – Motor side effects – Prolactin elevation • The man-in-the-arena algorithm www.mghcme.org Receptor profile and side effects • Alpha-1 – Hypotension: slow titration • Dopamine-2 – Dystonia: prophylactic anticholinergic – Akathisia, parkinsonism, tardive dyskinesia – Hyperprolactinemia • Histamine-1 – Sedation – Weight gain
    [Show full text]
  • Aldrich Raman
    Aldrich Raman Library Listing – 14,033 spectra This library represents the most comprehensive collection of FT-Raman spectral references available. It contains many common chemicals found in the Aldrich Handbook of Fine Chemicals. To create the Aldrich Raman Condensed Phase Library, 14,033 compounds found in the Aldrich Collection of FT-IR Spectra Edition II Library were excited with an Nd:YVO4 laser (1064 nm) using laser powers between 400 - 600 mW, measured at the sample. A Thermo FT-Raman spectrometer (with a Ge detector) was used to collect the Raman spectra. The spectra were saved in Raman Shift format. Aldrich Raman Index Compound Name Index Compound Name 4803 ((1R)-(ENDO,ANTI))-(+)-3- 4246 (+)-3-ISOPROPYL-7A- BROMOCAMPHOR-8- SULFONIC METHYLTETRAHYDRO- ACID, AMMONIUM SALT PYRROLO(2,1-B)OXAZOL-5(6H)- 2207 ((1R)-ENDO)-(+)-3- ONE, BROMOCAMPHOR, 98% 12568 (+)-4-CHOLESTEN-3-ONE, 98% 4804 ((1S)-(ENDO,ANTI))-(-)-3- 3774 (+)-5,6-O-CYCLOHEXYLIDENE-L- BROMOCAMPHOR-8- SULFONIC ASCORBIC ACID, 98% ACID, AMMONIUM SALT 11632 (+)-5-BROMO-2'-DEOXYURIDINE, 2208 ((1S)-ENDO)-(-)-3- 97% BROMOCAMPHOR, 98% 11634 (+)-5-FLUORODEOXYURIDINE, 769 ((1S)-ENDO)-(-)-BORNEOL, 99% 98+% 13454 ((2S,3S)-(+)- 11633 (+)-5-IODO-2'-DEOXYURIDINE, 98% BIS(DIPHENYLPHOSPHINO)- 4228 (+)-6-AMINOPENICILLANIC ACID, BUTANE)(N3-ALLYL)PD(II) CL04, 96% 97 8167 (+)-6-METHOXY-ALPHA-METHYL- 10297 ((3- 2- NAPHTHALENEACETIC ACID, DIMETHYLAMINO)PROPYL)TRIPH 98% ENYL- PHOSPHONIUM BROMIDE, 12586 (+)-ANDROSTA-1,4-DIENE-3,17- 99% DIONE, 98% 13458 ((R)-(+)-2,2'- 963 (+)-ARABINOGALACTAN BIS(DIPHENYLPHOSPHINO)-1,1'-
    [Show full text]
  • The Repurposing Drugs in Oncology Database
    ReDO_DB: the repurposing drugs in oncology database Pan Pantziarka1,2, Ciska Verbaanderd1,3, Vidula Sukhatme4, Rica Capistrano I1, Sergio Crispino1, Bishal Gyawali1,5, Ilse Rooman1,6, An MT Van Nuffel1, Lydie Meheus1, Vikas P Sukhatme4,7 and Gauthier Bouche1 1The Anticancer Fund, Brussels, 1853 Strombeek-Bever, Belgium 2The George Pantziarka TP53 Trust, London, UK 3Clinical Pharmacology and Pharmacotherapy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium 4GlobalCures Inc., Newton, MA 02459 USA 5Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115 USA 6Oncology Research Centre, Vrije Universiteit Brussel, Brussels, Belgium 7Emory University School of Medicine, Atlanta, GA 30322 USA Correspondence to: Pan Pantziarka. Email: [email protected] Abstract Repurposing is a drug development strategy that seeks to use existing medications for new indications. In oncology, there is an increased level of activity looking at the use of non-cancer drugs as possible cancer treatments. The Repurposing Drugs in Oncology (ReDO) project has used a literature-based approach to identify licensed non-cancer drugs with published evidence of anticancer activity. Data from 268 drugs have been included in a database (ReDO_DB) developed by the ReDO project. Summary results are outlined and an assessment Research of clinical trial activity also described. The database has been made available as an online open-access resource (http://www.redo-project. org/db/). Keywords: drug repurposing, repositioning, ReDO project, cancer drugs, online database Published: 06/12/2018 Received: 27/09/2018 ecancer 2018, 12:886 https://doi.org/10.3332/ecancer.2018.886 Copyright: © the authors; licensee ecancermedicalscience.
    [Show full text]
  • List of Vital Essential and Necessary Drugs and Medical Sundries For
    LIST OF VITAL ESSENTIAL AND NECESSARY DRUGS AND 2015 MEDICAL SUNDRIES FOR PUBLIC HEALTH INSTITUTIONS Sixth Edition STANDARDS & REGULATION DIVISION JAMAICA List of Vital Essential and Necessary List of Drugs and Medical Sundries for Public Institutions List of Vital Essential and Necessary List of Drugs and Medical Sundries for Public Institutions CONTENTS CONTENTS Contd. Page Preface 5-6 Page Information on Hospitals and Health Centres 7 Explanatory Notes 8 Medical Sundries 69-73 Prescription Writing 9-10 Dental Supplies 74 Algorithm for Treatment of Hypertension 11-12 Radiotherapy – Diagnostic Agents 75 Algorithm for Management of Type 2 Diabetes 13-14 Raw Materials 76 List of Drugs Designated for NHF 15-17 List of Drugs Designated for JADEP 18 VOLUME11 – SPECIALIST LIST 77 VOLUME 1 – GENERAL LIST 19 CLASSIFICATION OF DRUGS SECTION 1. Cardiovascular System 78 CLASSIFICATION OF DRUGS SECTION 2. Central Nervous System 79 SECTION 1. Cardiovascular System 20-24 SECTION 3. Dermatology 80 SECTION 2. Central Nervous System 25-30 SECTION 4. Endocrine System 80 SECTION 3. Dermatology 31-33 SECTION 5. Gastro-intestinal System 81 SECTION 4. Ear, Nose and Oropharynx 34-35 SECTION 6. Infections 81 SECTION 5. Endocrine System 36-38 SECTION 7. Malignant Disease and SECTION 6. Gastro-intestinal System 39-40 Immunosuppression 82 SECTION 7. Infections 41-46 SECTION 8. Musculoskeletal and Joint Diseases 83 SECTION 8. Malignant Disease and SECTION 9. Ophthalmology 83 Immunosuppression 47-49 SECTION 10. Genito-Urinary Tract Disorders 84 SECTION 9. Musculoskeletal and Joint Diseases 50-51 SECTION 11. Respiratory System 84 SECTION 10. Nutrition and Blood 52-54 SECTION 12.
    [Show full text]
  • Drug-Induced Movement Disorders
    Medical Management of Early PD Samer D. Tabbal, M.D. May 2016 Associate Professor of Neurology Director of The Parkinson Disease & Other Movement Disorders Program Mobile: +961 70 65 89 85 email: [email protected] Conflict of Interest Statement No drug company pays me any money Outline So, you diagnosed Parkinson disease .Natural history of the disease .When to start drug therapy? .Which drug to use first for symptomatic treatment? ● Levodopa vs dopamine agonist vs MAOI Natural History of Parkinson Disease Before levodopa: Death within 10 years After levodopa: . “Honeymoon” period (~ 5-7 years) . Motor (ON/OFF) fluctuations & dyskinesias: ● Drug therapy effective initially ● Surgical intervention by 10-15 years - Deep brain stimulation (DBS) therapy Motor Response Dyskinesia 5-7 yrs >10 yrs Dyskinesia ON state ON state OFF state OFF state time time Several days Several hours 1-2 hour Natural History of Parkinson Disease Prominent gait impairment and autonomic symptoms by 20-25 years (Merola 2011) Behavioral changes before or with motor symptoms: . Sleep disorders . Depression . Anxiety . Hallucinations, paranoid delusions Dementia at anytime during the illness . When prominent or early: diffuse Lewy body disease Symptoms of Parkinson Disease Motor Symptoms Sensory Symptoms Mental Symptoms: . Cognitive and psychiatric Autonomic Symptoms Presenting Symptoms of Parkinson Disease Mood disorders: depression and lack of motivation Sleep disorders: “acting out dreams” and nightmares Early motor symptoms: Typically Unilateral . Rest tremor: chin, arms or legs or “inner tremor” . Bradykinesia: focal and generalized slowness . Rigidity: “muscle stiffness or ache” Also: (usually no early postural instability) . Facial masking with hypophonia: “does not smile anymore” or “looks unhappy all the time” .
    [Show full text]
  • 2009 Paris, France the Movement Disorder Society’S 13Th International Congress of Parkinson’S Disease and Movement Disorders
    FINAL PROGRAM The Movement Disorder Society’s 13th International Congress OF PARKINSon’S DISEASE AND MOVEMENT DISORDERS JUNE 7-11, 2009 Paris, France The Movement Disorder Society’s 13th International Congress of Parkinson’s Disease and Movement Disorders Claiming CME Credit To claim CME credit for your participation in the MDS 13th International Congress of Parkinson’s Disease and Movement Disorders, International Congress participants must complete and submit an online CME Request Form. This Form will be available beginning June 10. Instructions for claiming credit: • After June 10, visit www.movementdisorders.org/congress/congress09/cme • Log in following the instructions on the page. You will need your International Congress Reference Number, located on the upper right of the Confirmation Sheet found in your registration packet. • Follow the on-screen instructions to claim CME Credit for the sessions you attended. • You may print your certificate from your home or office, or save it as a PDF for your records. Continuing Medical Education The Movement Disorder Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Credit Designation The Movement Disorder Society designates this educational activity for a maximum of 30.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. Non-CME Certificates of Attendance were included with your on- site registration packet. If you did not receive one, please e-mail [email protected] to request one. The Movement Disorder Society has sought accreditation from the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists.
    [Show full text]
  • Substituted 3-Isobutyl-9, 10-Dimethoxy-1,3,4,6,7,11B
    (19) TZZ Z_ 9B_T (11) EP 2 081 929 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C07D 471/04 (2006.01) 09.01.2013 Bulletin 2013/02 (86) International application number: (21) Application number: 07864160.2 PCT/US2007/084176 (22) Date of filing: 08.11.2007 (87) International publication number: WO 2008/058261 (15.05.2008 Gazette 2008/20) (54) SUBSTITUTED 3-ISOBUTYL-9, 10-DIMETHOXY-1,3,4,6,7,11B-HEXAHYDRO-2H-PYRIDO[2,1-A] ISOQUINOLIN-2-OL COMPOUNDS AND METHODS RELATING THERETO SUBSTITUIERTE 3-ISOBUTYL-9,10-DIMETHOXY-1,3,4,6,7,11B-HEXAHYDRO-2H-PYRIDO[2,1-A] ISOCHINOLIN-2-OLVERBINDUNGEN UND DIESE BETREFFENDE VERFAHREN COMPOSÉS 3-ISOBUTYL-9, 10-DIMÉTHOXY-1,3,4,6,7,11B-HEXAHYDRO-2H-PYRIDO[2,1-A] ISOQUINOLIN-2-OL SUBSTITUÉS ET PROCÉDÉS ASSOCIÉS (84) Designated Contracting States: (56) References cited: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR • BROSSIA ET AL: "SYNTHESEVERSUCHE IN DER HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE EMETIN-REIHE 3. MITTEILUNG 2-HYDROXY- SI SK TR HYDROBENZOÄAÜCHINOLIZINE" HELVETICA Designated Extension States: CHIMICA ACTA, VERLAG HELVETICA CHIMICA AL BA HR MK RS ACTA. BASEL, CH, vol. 41, no. 4, 1958, pages 1793-1806, XP008047475 ISSN: 0018-019X (30) Priority: 08.11.2006 US 864944 P • KILBOURN M R ET AL: "Absolute Configuration of (+)-alpha-Dihydrotetrabenazine, an Active (43) Date of publication of application: Metabolite of Tetrabenazine" CHIRALITY, WILEY- 29.07.2009 Bulletin 2009/31 LISS, NEW YORK, US, vol.
    [Show full text]
  • Tetrabenazine: the First Approved Drug for the Treatment of Chorea in US Patients with Huntington Disease
    Neuropsychiatric Disease and Treatment Dovepress open access to scientific and medical research Open Access Full Text Article REVIEW 7HWUDEHQD]LQHWKHÀUVWDSSURYHGGUXJ for the treatment of chorea in US patients with Huntington disease Samuel Frank Abstract: Huntington disease (HD) is a dominantly inherited progressive neurological disease Boston University School of Medicine, characterized by chorea, an involuntary brief movement that tends to flow between body regions. Boston, Massachusetts, USA HD is typically diagnosed based on clinical findings in the setting of a family history and may be confirmed with genetic testing. Predictive testing is available to those at risk, but only experienced clinicians should perform the counseling and testing. Multiple areas of the brain degenerate mainly involving the neurotransmitters dopamine, glutamate, and G-aminobutyric acid. Although pharmacotherapies theoretically target these neurotransmitters, few well-conducted trials for symptomatic or neuroprotective interventions yielded positive results. Tetrabenazine (TBZ) is a dopamine-depleting agent that may be one of the more effective agents for reducing chorea, although it has a risk of potentially serious adverse effects. Some newer antipsychotic agents, such as olanzapine and aripiprazole, may have adequate efficacy with a more favorable adverse-effect profile than older antipsychotic agents for treating chorea and psychosis. This review will address the epidemiology and diagnosis of HD as background for understanding potential pharmacological treatment options. Because TBZ is the only US Food and Drug Administration-approved medication in the United States for HD, the focus of this review will be on its pharmacology, efficacy, safety, and practical uses. There are no current treatments to change the course of HD, but education and symptomatic therapies can be effective tools for clinicians to use with patients and families affected by HD.
    [Show full text]
  • Screening of 300 Drugs in Blood Utilizing Second Generation
    Forensic Screening of 300 Drugs in Blood Utilizing Exactive Plus High-Resolution Accurate Mass Spectrometer and ExactFinder Software Kristine Van Natta, Marta Kozak, Xiang He Forensic Toxicology use Only Drugs analyzed Compound Compound Compound Atazanavir Efavirenz Pyrilamine Chlorpropamide Haloperidol Tolbutamide 1-(3-Chlorophenyl)piperazine Des(2-hydroxyethyl)opipramol Pentazocine Atenolol EMDP Quinidine Chlorprothixene Hydrocodone Tramadol 10-hydroxycarbazepine Desalkylflurazepam Perimetazine Atropine Ephedrine Quinine Cilazapril Hydromorphone Trazodone 5-(p-Methylphenyl)-5-phenylhydantoin Desipramine Phenacetin Benperidol Escitalopram Quinupramine Cinchonine Hydroquinine Triazolam 6-Acetylcodeine Desmethylcitalopram Phenazone Benzoylecgonine Esmolol Ranitidine Cinnarizine Hydroxychloroquine Trifluoperazine Bepridil Estazolam Reserpine 6-Monoacetylmorphine Desmethylcitalopram Phencyclidine Cisapride HydroxyItraconazole Trifluperidol Betaxolol Ethyl Loflazepate Risperidone 7(2,3dihydroxypropyl)Theophylline Desmethylclozapine Phenylbutazone Clenbuterol Hydroxyzine Triflupromazine Bezafibrate Ethylamphetamine Ritonavir 7-Aminoclonazepam Desmethyldoxepin Pholcodine Clobazam Ibogaine Trihexyphenidyl Biperiden Etifoxine Ropivacaine 7-Aminoflunitrazepam Desmethylmirtazapine Pimozide Clofibrate Imatinib Trimeprazine Bisoprolol Etodolac Rufinamide 9-hydroxy-risperidone Desmethylnefopam Pindolol Clomethiazole Imipramine Trimetazidine Bromazepam Felbamate Secobarbital Clomipramine Indalpine Trimethoprim Acepromazine Desmethyltramadol Pipamperone
    [Show full text]